2020 dividend forecasts: BP, Vodafone and Astrazeneca

Paul Summers takes a look at what income investors might expect from three FTSE 100 (INDEXFTSE:UKX) favourites next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Earlier this month, my Foolish colleague Edward Sheldon looked at the dividend credentials of FTSE 100 financial giants Lloyds and Barclays, as well as revived supermarket Tesco going into 2020. Today, I’m doing the same with three other stocks, all of which are popular with those investing for income.

As Edward quite rightly stated back then, please remember that the numbers stated below are subject to change, particularly as we could see quite a bit of movement in the market before and after the election

BP

FY2020 dividend forecast: 41.2 cents (32p)
FY2020 prospective yield: 6.41%

Oil behemoth BP (LSE: BP) hasn’t had the best time of late, giving away the gains it had made in the first few months of 2019 over the second half of the year due to a falling oil price. That said, a lower valuation means the dividend yield now stands at 6.41% — more than the FTSE 100 average and slightly higher than Royal Dutch Shell. This payout is likely to be covered by earnings almost 1.4 times. That’s a little lower than I would normally like, but certainly better than it once was.

As always, a lot depends on things BP can’t control. Assuming 2020 brings the black gold bulls back from the shadows, however, now might be as good a time as any to invest.  

Vodafone

FY2021 dividend forecast: 9.4 cents (8.1p)
FY2021 prospective yield: 5.17%

There was a time when I would avoid shares in Vodafone (LSE: VOD) like the plague thanks to its dogged refusal to reduce its unaffordable dividend. Now that this has finally happened, I’m prepared to be a little more welcoming. Considering that its share price has climbed 19% since the announcement back in May, it seems I’m not alone. 

That’s not to say that I think income investors should necessarily pile into the stock. Vodafone’s proposed 9.4 cents per share cash return in FY2021 (beginning 1 April 2020) will still only be covered just 1.1 times by expected profits. Moreover, the company still carries an extraordinary amount of debt on its balance sheet — the reduction of which will depend on its ability to offload its European mobile mast business and continue taking contracts from rivals (the recent capture of Virgin Media from BT is an example). 

2019 could go down as the year that Vodafone’s fortunes began to turn, but I’d still proceed with caution. 

Astrazeneca

FY2020 dividend forecast: 275 cents (214p)
FY2020 prospective yield: 2.89%

Pharmaceutical powerhouse Astrazeneca (LSE: AZN) has been one of the index’s standout performers in 2019 with the share price a little over 25% higher today than where it was at the start of the year.

In contrast to the situation at BP, this has resulted in Astra’s yield moving lower. The firm is expected to return around 214p per share in FY2020 which equates to a yield of just 2.89%. Positively, dividend cover has improved over recent years and next year’s cash payout should be covered around 1.56 times by profits.

My only real concern with Astrazeneca right now is that the stock looks expensive relative to the general market and to peer GlaxoSmithKline (at 27 vs 14 times forecast earnings). Should sterling rise on December 13 following a perceived breakthrough on Brexit, it’s possible the former’s share price could come off the boil (since Astra makes most of its money overseas). As such, anyone considering the stock may wish to put off their purchase for now.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using smartphone at home, watching stock charts.
Investing Articles

2 spectacular growth stocks to consider buying in March

Investors ignore the risks with growth stocks when things are going well. But when this changes, fixating on the dangers…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Why is the FTSE 100 suddenly beating the S&P 500?

The UK's blue-chip index has been on fire over the past couple of years, helping it catch up to the…

Read more »

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

This non-oil FTSE stock’s risen 4.6% in 3 days. What’s going on?

Against the backdrop of trouble in the Middle East, James Beard investigates why this FTSE 100 stock’s doing so well.…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Has a 2026 stock market crash just come a whole lot closer?

If we're in for a stock market crash, what's the best way for us to prepare, and what kinds of…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Up 79% in a year, this FTSE 250 stock still gets a resounding Strong Buy from analysts

This under-the-radar growth stock in the FTSE 250 has been on fire over the past 12 months. Why are City…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Vistry shares down 20%! Here’s what I’m doing…

Vistry shares have crashed as the firm cuts prices and moves away from share buybacks. But is Stephen Wright’s long-term…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

The IAG share price is climbing today despite war fears – what’s going on?

It's been a tough week for the IAG share price and Harvey Jones expects more volatility. Yet the FTSE 100…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

By March 2027, £1,000 invested in Natwest shares could turn into…

NatWest shares have been on a tear in recent years. What might the next 12 months have in store for…

Read more »